Tim-3(+) DC of tumor-bearing mice treated with gal-9 increased the number of IFN-γ-producing CD8(+) T cells, thereby enhancing the anti-tumor immunity mediated by CD8(+) T cells (Nagahara et al., 2008). This evidence concerns the gene HAVCR2 and neoplasm.